LIGAND PHARMACEUTICALS

Company snapshot

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient

• 34 active pipeline program(s) linked via ClinicalTrials.gov.
• 133 US patent(s) indexed to this assignee profile.
• 34 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for LIGAND PHARMACEUTICALS. Not investment advice.

• Peer + 0 momentum

  United Therapeutics Europe

  TA overlap score 40

• Peer + 0 momentum

  Takeda

  TA overlap score 40

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 40

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  Quantum Pharmaceuticals

  TA overlap score 23.6

• Peer + 0 momentum

  Prime Medicine

  TA overlap score 23.4

Recent activity

Latest pipeline, patent, and corporate events for LIGAND PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   Ramipril tablet 10 mg — Phase 1

2. Jun 8, 2026 Clinical update

   Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg — Phase 1

3. Jun 8, 2026 Clinical update

   ONTAK (denileukin difitox, DAB389IL-2) — Approved

4. Jun 8, 2026 Clinical update

   Intravenous Carbamazepine (IV CBZ) — Phase 3

5. Jun 8, 2026 Clinical update

   erlotinib (Tarceva) and bexarotene (Targretin) — Unknown

View all clinical trial activity →

• What is LIGAND PHARMACEUTICALS?

  Ligand Pharmaceuticals is a pharma organization headquartered in Jupiter, USA. It trades on NYSE under ticker LGND. Primary therapeutic focus areas include Carcinoma, Non-small-cell Lung, Type 2 Diabetes Mellitus, Sarcoma, Kaposi, Seasonal Allergic Rhinitis, Hypertension. NovaPha

• Is LIGAND PHARMACEUTICALS publicly traded?

  Yes. LIGAND PHARMACEUTICALS is listed with ticker LGND on NYSE per SEC EDGAR records linked on this profile.

• What drugs does LIGAND PHARMACEUTICALS develop or market?

  We link 25 drug profile(s) where LIGAND PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ligand-pharmaceuticals-inc#company-drugs.

• What are the latest developments for LIGAND PHARMACEUTICALS?

  In the last 12 months our linked public records show 34 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does LIGAND PHARMACEUTICALS focus on?

  LIGAND PHARMACEUTICALS focuses on Carcinoma, Non-small-cell Lung, Type 2 Diabetes Mellitus, Sarcoma, Kaposi based on our analysis of their pipeline programs and drug development activities.